Catalog No.
Product Name
Application
Product Information
Citations
-
Ubiquitin ligase inducer
Lenalidomide is a derivative of thalidomide. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the micro environment support for tumor cells, and immunomodulatory role. It induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.- Kazuya Ishiguro, .et al. , Cancer Lett, 2025, Oct 28:631:217941 PMID: 40701319
- Sumie Fujii, .et al. , Stem Cells and Development, 2025, 34: 9-10 PMID: 40130551
- Daniel A. Rauch, .et al. , Retrovirology, 2020, 17: 27 PMID: 32859220
- A Hayano, .et al. , Int J Clin Oncol, 2019, 1-10 PMID: 30993483
- Kumar R, .et al. , Mol Biol Rep, 2018, Oct 11 PMID: 30311125
- Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Cyclosporin A (Cyclosporine A) is an immunosuppressant agent widely used in post-allogeneic organ transplant to reduce the activity of the immune system.
- X Jia, .et al. , J Hazard Mater, 2020, Jun 4;399:123034 PMID: 32544768
- Y Huang, .et al. , Experimental and Therapeutic Medicine, 2020, 20(2), 736-747 PMID: 32742319
- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
-
TNF-alpha inhibitor
Pomalidomide is a derivative of thalidomide and acts as an immunomodulator. -
BRD42/BRD4 Degrader
IBG1 is a molecular glue degrader that selectively targets BRD2 and BRD4, exhibiting a degradation capability with a DC50 of 0.15 nM. Notably, IBG1 does not significantly impact the paralogue BRD3. This compound effectively inhibits the growth of cancer cells and is a valuable tool for research focused on tumor biology and therapeutic strategies. -
CDK2 molecular glue Degrader
CDK2 degrader 1 is a selective molecular glue degrader targeting cyclin-dependent kinase 2 (CDK2). It effectively induces ubiquitination and proteasomal degradation of CDK2 by binding to cereblon, achieving a Dmax greater than 80% and a Ki greater than 1 μM. This compound is utilized in cancer research, providing insights into tumor biology and potential therapeutic strategies. -
IKZF2/CK1α Molecular Gel
DEG-77 is a molecular glue that targets IKZF2 and CK1α, demonstrating DC50 values of 15.3 nM and 10 nM, respectively. This compound exerts notable anti-tumor effects by enhancing the transcription of the pro-apoptotic protein Bax and promoting the expression of the cell cycle regulator p21. DEG-77 is relevant for research in acute myeloid leukemia (AML), diffuse large B-cell lymphoma, and ovarian cancer. -
Molecular Glue Degrader
BTX306 is a cereblon-targeting molecular glue degrader that effectively reduces myeloma cell viability and induces apoptosis. This compound demonstrates the ability to overcome resistance in myeloma cells to traditional therapies such as Lenalidomide and Bortezomib. Additionally, BTX306 displays potent activity against primary myeloma cells and exhibits substantial efficacy in in vivo models. This reagent is suitable for research focusing on myeloma and related therapeutic strategies. -
Molecular Glue GSPT1 Degrader
TD-522 is a potent and selective molecular glue targeting GSPT1 for degradation, exhibiting a DC50 of 0.269 nM. This compound demonstrates significant anti-proliferative activity and induces apoptosis in acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) cell lines. Additionally, TD-522 effectively suppresses tumor growth in a TMD-8 xenograft model. It is applicable for research focused on AML and DLBCL. -
CK1α Molecular Glue
BMS-986397 is a selective and orally active cereblon-based molecular glue degrader targeting casein kinase 1α (CK1α). This compound effectively induces apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells, positioning it as a valuable tool for research in the fields of AML and high-risk myelodysplastic syndromes (HR-MDS). Its unique mechanism offers potential for elucidating CK1α's role in these malignancies. -
CRY1 Molecular Glue Degrader
M47 is a molecular glue degrader that specifically targets Cryptochrome 1 (CRY1), promoting its degradation within the nucleus. This compound has been shown to enhance apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and prolong lifespan in p53 knockout mice. M47 serves as a valuable tool for research focused on cancer biology and the mechanisms of targeted protein degradation. -
BTK/GSPT1 Degrader
GBD-9 is a dual-action degrader that targets both BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). It acts as a PROTAC to promote BTK degradation and functions as a molecular glue to induce GSPT1 degradation. GBD-9 exhibits significant antiproliferative activity in cancer cells, making it a promising candidate for cancer research. - Tz-Thalidomide is a tetrazine-tagged thalidomide derivative that functions as a ligand for E3 ligases. It exhibits binding affinity for BRD4, with IC₅₀ values of 46.25 μM for BRD4-1 and 62.55 μM for BRD4-2. As a click chemistry reagent, Tz-Thalidomide contains a tetrazine moiety capable of undergoing inverse electron demand Diels–Alder (iEDDA) reactions with trans-cyclooctene (TCO)-containing molecules, enabling bioorthogonal labeling and conjugation applications.
-
GSPT1 degrader
LYG-409 is an orally active degrader of GSPT1 that demonstrates potent antitumor activity in vivo, with tumor growth inhibition (TGI) rates of 94.34% in acute myeloid leukemia and 104.49% in prostate cancer models. In vitro, LYG-409 inhibits KG-1 cells through GSPT1 degradation, with an IC₅₀ of 9.50 nM and a DC₅₀ of 7.87 nM. -
Molecular glues
ERAS-0015 (Pan-RAS-IN-2) is a molecular glue that targets RAS by promoting the formation of ternary complexes with cyclophilin A (CYPA) and active RAS (ON) proteins. This interaction disrupts the binding of RAF to RAS, thereby inhibiting downstream signaling. Pan-rasin-2 exhibits significant antiproliferative activity in RAS-mutant cell lines and shows promise as an anti-tumor agent. -
two-site molecular glue
LL-K12-18 is a two-site molecular glue that enhances the protein-protein interaction between CDK12 and DDB1, stabilizing the complex and promoting cyclin K degradation with an EC50 of 0.37 nM. It exhibits potent transcriptional repression and anti-proliferative activity in tumor cells, making it a valuable tool for cancer research. -
CK1α degrader
TMX-4116 is a selective degrader of casein kinase 1α (CK1α), demonstrating preferential degradation activity with DC₅₀ values below 200 nM in MOLT4, Jurkat, and MM.1S cell lines. By targeting CK1α for proteasomal degradation, TMX-4116 offers a promising tool for investigating CK1α function and holds potential for therapeutic research in multiple myeloma and related hematologic malignancies. -
CK1α molecular glue degrader
SJ3149 is a selective and potent molecular glue degrader that targets casein kinase 1α (CK1α) for proteasomal degradation. By promoting CK1α elimination, SJ3149 exhibits broad antiproliferative activity across various cancer models. It serves as a valuable tool for exploring CK1α-dependent signaling pathways and holds promise for therapeutic development in oncology research. -
PDE6D/IKZF1/IKZF3/CK1α Degrader
FPFT-2216 is a “molecular glue” degrader that facilitates the proteasomal degradation of multiple target proteins, including phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), as well as casein kinase 1α (CK1α). By promoting selective ubiquitination through E3 ligase recruitment, FPFT-2216 modulates key regulatory pathways and holds promise for research in oncology and inflammatory diseases. -
VAV1 Molecular Glue Degrader
VAV1 degrader-3 is an orally active VAV1 molecular glue degrader with a DC50 of 7 nM. It effectively reduces immune cell activation, proliferation, and cytokine production, making it a valuable tool for studying inflammatory and autoimmune disorders. Additionally, VAV1 degrader-3 demonstrates inhibition of disease progression in experimental models such as experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). -
Molecular Glue
MNN-02-155 is a bivalent molecular glue that binds simultaneously to p300/CBP and BCL6. This compound effectively activates the BCL6-target reporter gene, leading to significant induction of cell death. MNN-02-155 is particularly relevant for research into diffuse large B cell lymphomas (DLBCLs), providing insights into potential therapeutic strategies involving BCL6 modulation. -
ZBTB7A/WIZ Dual Molecular Glue Degrader
BMS-986470 is a dual molecular glue degrader that targets ZBTB7A and WIZ through modulation of the CRBN E3 ligase. This compound demonstrates potent induction of γ-globin, making it a valuable tool for studying hemoglobin disorders. BMS-986470 holds significant potential for research applications related to sickle cell disease (SCD), facilitating investigations into therapeutic strategies and molecular mechanisms underlying the condition. -
Molecular Glue
TCIP3 is a bivalent molecular glue that targets p300/CBP and BCL6. By redirecting p300 and CBP, TCIP3 activates programmed cell death genes that are typically suppressed by the oncogenic driver BCL6, making it a valuable tool for investigating diffuse large B cell lymphomas (DLBCLs). Importantly, TCIP3 demonstrates no toxicity to non-transformed tonsillar lymphocytes or fibroblasts, ensuring the safety of experimental applications. -
WIZ Molecular Glue
WIZ degrader 8 is a selective degrader targeting the transcription factor WIZ, promoting the degradation of WIZ and subsequently inducing the expression of fetal hemoglobin (HbF). This compound has significant potential for research applications related to sickle cell disease, as it may serve as a therapeutic strategy to modulate HbF levels and alleviate disease symptoms. -
Molecular Glues
Lenalidomide hemihydrate functions as a molecular glue through its activity as an immunomodulator. This compound selectively binds to the ubiquitin E3 ligase cereblon (CRBN), leading to the ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 complex. Lenalidomide hemihydrate is effective in inhibiting the proliferation of mature B-cell lymphomas, including multiple myeloma, and promotes the release of IL-2 from T cells, making it a valuable tool in cancer research. -
SKP2 Molecular Glue Degrader
XMU-MP-8 is a potent molecular glue degrader that targets the oncoprotein SKP2. It binds to the F-box domain of SKP2 and the N-terminal TPR domain of the E3 ligase STUB1, facilitating the formation of a stable SKP2-SKPer1-STUB1 ternary complex. This interaction leads to SKP2 ubiquitination and subsequent proteasomal degradation, selectively eliminating SKP2-expressing cancer cells. XMU-MP-8 demonstrates significant tumor suppression and favorable safety profiles in vivo, making it a valuable tool for cancer research, particularly in studies related to non-small cell lung adenocarcinoma (NSCLC) and prostatic adenocarcinoma. -
TRIM21 Molecular Glue
HGC652 is a molecular glue degrader that specifically targets TRIM21, facilitating the disruption of nuclear membrane integrity through a TRIM21-dependent mechanism. By binding with high affinity to the PRY-SPRY domain of TRIM21, HGC652 promotes the interaction between TRIM21 and NUP98, enhancing E3 ligase activity. This results in the polyubiquitination and subsequent proteasomal degradation of nucleoporins such as NUP155 and GLE1, leading to altered nuclear morphology, enhanced genomic instability, and ultimately, cancer cell death. HGC652 serves as a valuable tool for investigating nuclear envelope dynamics and the role of TRIM21 in cancer research. -
Molecular Glue
CC-647 is a molecular glue modulator that targets the Cereblon (CRBN) E3 ubiquitin ligase. It enhances the interaction between CRBN and ZBTB16, along with its oncogenic fusion protein RARα-ZBTB16, with a DC50 of 103 nM. CC-647 is particularly valuable for the investigation of ZBTB16-RARα-associated acute promyelocytic leukemia (APL) and offers potential insights into therapeutic strategies for this malignancy. -
Molecular Glues
MG Degrader 3 is a molecular glue that targets the CRBN protein, inducing targeted protein degradation. It exhibits potent anti-proliferative activity in multiple myeloma cell line MM.1S, with an IC50 of 8.7 nM. This compound is valuable for studies investigating protein degradation mechanisms and therapeutic approaches in cancer research. -
Molecular Glue BRD4 Degrader
BRD4 degrader-1 is a monovalent, covalent molecular glue that specifically targets BRD4, a key regulator in various cellular processes. By engaging DCAF16, an E3 ubiquitin ligase, this compound facilitates the degradation of both long and short isoforms of BRD4 within the cellular context. Its mechanism of action makes BRD4 degrader-1 a valuable tool for research applications aimed at understanding and manipulating BRD4-related pathways in cancer and other diseases. -
Molecular Glue
AMPTX-1 is a molecular glue that functions as a selective, reversibly covalent degrader of BRD9, promoting its recruitment to the E3 ubiquitin ligase DCAF16. This compound exhibits significant activity in inducing proteasomal degradation of BRD9, making it a valuable tool for research involving chromatin regulation and cellular signaling pathways. AMPTX-1 can be utilized in studies focused on targeted protein degradation and the modulation of BRD9-related biological processes. -
SMARCA2/4 Molecular Glue Degrader
SMARCA2/4 degrader-1 is a molecular glue degrader specifically targeting SMARCA2 and SMARCA4, exhibiting a DC50 value of 2.2 nM for SMARCA4. This compound functions by covalently bridging CUL4DCAF16 and CRL1FBXO22, leading to the efficient degradation of SMARCA2 and SMARCA4 proteins. It is utilized in research to understand the roles of these proteins in various biological processes and disease states, particularly in cancer biology and epigenetic regulation. -
Molecular Glue BRD4 Degrader
BRD4 degrader-2 (Compound JP-2-197) is a covalent monovalent molecular glue that selectively targets BRD4 for degradation by inducing a ternary complex with RNF126, an E3 ligase. This compound effectively promotes the degradation of both the long and short isoforms of BRD4 within cellular contexts. It serves as a valuable tool for investigating the roles of BRD4 in various biological processes and disease states, particularly in cancer research and therapeutic development. -
BRD9 Molecule Glue
BRD9 Degrader-3 is a molecular glue targeting BRD9, exhibiting a DC50 of less than 1.25 nM. This compound facilitates the proteolytic degradation of BRD9, effectively modulating protein levels within cellular systems. It is primarily utilized in research applications aimed at investigating the role of BRD9 in cancer biology and other disease contexts. -
RAF Molecular Glue
NST-628 is a molecular glue targeting RAF within the MAPK signaling pathway. It disrupts RAF phosphorylation and MEK activation by preventing the formation of BRAF-CRAF and BRAF-ARAF heterodimers. NST-628 exhibits significant biological activity in inhibiting RAS- and RAF-driven cancers, particularly in tumors with mutant KRAS, NRAS, BRAF class II/III, and NF1 mutations. This compound is a valuable tool for research into targeted cancer therapies and understanding the RAS-MAPK pathway's role in oncogenesis. -
Molecular Glue
OPB-171775 is an orally active molecular glue that targets phosphodiesterase 3A (PDE3A) and schlafen family member 12 (SLFN12). This compound induces SLFN12-mediated RNase activity, leading to subsequent cell death. Additionally, OPB-171775 activates the GCN2 signaling pathway associated with SLFN12, showcasing its significant efficacy in combating gastrointestinal stromal tumors. Researchers can utilize OPB-171775 to explore pathways in cancer biology and investigate the therapeutic potential of molecular glues in tumor treatment. -
Molecule Glue
HuR degrader 2 is a molecular glue that specifically targets the RNA-binding protein Hu antigen R (HuR), leading to a significant degradation of approximately 30% of HuR at a concentration of 0.1 μM. This compound effectively inhibits the proliferation of the Colo-205 cancer cell line, demonstrating an IC50 of ≤200 nM. Additionally, HuR degrader 2 shows a high affinity for cereblon, with an HTRF ratio of less than 0.02, making it a valuable tool for studying HuR's role in cancer biology. -
Molecular Glue
MG-HuR2 is a molecular glue degrader that specifically targets the oncogenic RNA-binding protein HuR, exhibiting an IC50 of 0.5 μM. This compound is particularly relevant for research involving HuR-overexpressing malignancies, such as breast cancer, providing a valuable tool for investigating therapeutic strategies aimed at modulating HuR activity in cancerous tissues. -
WEE1 Kinase Molecular Glue Degrader
BMS-986463 is a WEE1 kinase molecular glue degrader that functions as a CRBN E3 ligase modulator (CELMoD). It significantly inhibits tumor growth while reducing phospho-CDK2 levels, making it a valuable tool in cancer research. This compound is particularly relevant for studies focusing on advanced malignant solid tumors, including non-small cell lung cancer (NSCLC). -
Molecular Glue Degrader
WEE1 Degrader 1 is a CRBN-dependent molecular glue degrader that targets WEE1 and casein kinase 1α (CK1α) with sub-2 nM DC50 values for both proteins. This compound effectively induces the proteasomal degradation of its targets, providing a valuable tool for studying cell cycle regulation. WEE1 Degrader 1 is particularly relevant in the research of acute lymphoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, colorectal adenocarcinoma, and diffuse large B-cell lymphoma. -
SALL4/OSR1 Dual Molecular Glue Degrader
HRZ-01-082-5 is a dual-functional molecular glue degrader targeting SALL4 and OSR1, exhibiting a DC50 of 4.8 nM for OSR1. This compound effectively induces the degradation of both SALL4 and OSR1 via the CRBN mechanism. HRZ-01-082-5 is applicable in the study of heart and urogenital development as well as in cancer research, providing valuable insights into these critical biological processes. -
MYC Molecular Glues Degrader
MYC Degrader 1 is a potent molecular glue degrader that targets the MYC oncogene, facilitating the degradation of MYC proteins. This compound exhibits significant anti-tumor activity by restoring the functionality of the pRB1 protein, thereby reinstating the sensitivity of MYC-overexpressing cancer cells to CDK4/6 inhibitors. MYC Degrader 1 is suitable for research applications focusing on cancer therapeutics and the modulation of MYC-driven signaling pathways. -
Cyclin K Degrader
HQ461 is a molecular glue that facilitates the interaction between CDK12 and DDB1, leading to the targeted degradation of cyclin K. This degradation impairs CDK12 function, which in turn results in reduced phosphorylation of CDK12 substrates, downregulation of DNA damage response genes, and induces apoptosis in affected cells. HQ461 is a valuable tool for research applications focused on the modulation of cell cycle regulation and the DNA damage response pathway. -
CDK2 Molecular Glue Degrader
CDK2 degrader 6 is a potent CDK2 molecular glue degrader that functions through binding to cereblon and CDK2, leading to the ubiquitination and proteasomal degradation of CDK2. With a DC50 of 46.5 nM, it effectively modulates the cell cycle and reduces proliferation in breast cancer cells. Additionally, CDK2 degrader 6 demonstrates in vivo antitumor activity in gastric cancer mouse models, making it a valuable tool for research into breast and gastric cancers. -
Molecular Glue Degrader
dCeMM3 is a molecular glue degrader that facilitates the ubiquitination and subsequent degradation of cyclin K. By promoting the interaction of the CDK12-cyclin K complex with the CRL4B ligase complex, dCeMM3 plays a critical role in regulating cell cycle progression. This reagent is particularly useful for research applications focused on targeted protein degradation and the elucidation of CDK12-associated pathways. -
Molecular Glue Degrader
dCeMM2 is a molecular glue degrader that specifically targets cyclin K. It induces ubiquitination and subsequent degradation of cyclin K by facilitating the interaction between CDK12-cyclin K and the CRL4B ligase complex. This compound is valuable for studying the regulation of cell cycle and transcriptional processes, and it serves as a tool in research areas focusing on cancer biology and cell signaling pathways. -
Molecular Glue Degrader
dCeMM4 is a molecular glue degrader that targets cyclin K by inducing its ubiquitination and subsequent degradation. It facilitates the interaction between CDK12-cyclin K and the CRL4B ligase complex, leading to effective protein degradation. This compound is useful for research applications investigating cell cycle regulation and the ubiquitin-proteasome system. -
CDK2 Degrader
(R)-CDK2 Degrader 6 is a cereblon-based molecular glue degrader specifically targeting cyclin-dependent kinase 2 (CDK2). It functions by inducing ubiquitination and subsequent proteasomal degradation of CDK2, with a DC50 value of 27 nM. This compound is suitable for cancer research applications, providing a valuable tool for studying CDK2-related pathways and therapeutic interventions. -
CDK2 Molecular Glue Degrader
(S)-CDK2 degrader 6 selectively targets cyclin-dependent kinase 2 (CDK2) as a molecular glue degrader. With a DC50 of 166.7 nM over 24 hours, this compound effectively promotes the degradation of CDK2, thereby modulating cell cycle progression. It holds significant potential for applications in breast cancer research, enabling the exploration of therapeutic strategies that involve the regulation of CDK2 activity. -
Molecular Glues
CDK12 ligand-3 is a molecular glue that effectively targets and degrades the CDK12 protein, with a DC50 of 35 nM. This compound also influences the degradation of CDK13 and its regulatory partner, Cyclin K, while inhibiting serine 2 phosphorylation of the RNA polymerase II CTD. CDK12 ligand-3 demonstrates significant anti-proliferative effects on Jurkat cells and is applicable in cancer research, particularly in the study of leukemia.
